The recognition of LY6E as a promising objective for cancer intervention has initiated considerable effort. Various antibody agents are currently explored with the aim of selectively inhibiting LY6E's role and inducing an anti-cancer outcome in those diagnosed with multiple malignancies . Obstacles remain in improving antibody administration and ov